Entheon Biomedical Corp
Entheon Biomedical Corp. operates as a biotechnology research and development company. The company develops products for treating addiction and substance use disorders. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Entheon Biomedical Corp (ENTBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.265x
Based on the latest financial reports, Entheon Biomedical Corp (ENTBF) has a cash flow conversion efficiency ratio of -0.265x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-115.78K) by net assets ($436.14K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Entheon Biomedical Corp - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Entheon Biomedical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Entheon Biomedical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entheon Biomedical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HYUNGJI INNOVATION & CREATIVE Co.Ltd
KQ:011080
|
-0.071x |
|
SRIVARU Holding Limited
PINK:SVUHF
|
N/A |
|
OSHKOSH
BE:OK3
|
0.079x |
|
STATE STREET - Dusseldorf Stock Exchang
DU:ZYA
|
0.105x |
|
Pharmadrug Inc
PINK:LMLLF
|
0.007x |
|
Tie Holding NV
F:TJH7
|
0.652x |
|
ALPHA MOS INH.EO 020
F:0MV
|
N/A |
|
d'Alba Global
KO:483650
|
0.000x |
Annual Cash Flow Conversion Efficiency for Entheon Biomedical Corp (2018–2025)
The table below shows the annual cash flow conversion efficiency of Entheon Biomedical Corp from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $145.33K | $-355.64K | -2.447x | -114.68% |
| 2024-03-31 | $315.75K | $-359.93K | -1.140x | +64.58% |
| 2023-03-31 | $614.57K | $-1.98 Million | -3.218x | -1372.57% |
| 2022-03-31 | $9.05 Million | $-1.98 Million | -0.219x | +71.16% |
| 2021-03-31 | $3.74 Million | $-2.84 Million | -0.758x | -171.13% |
| 2020-03-31 | $1.69 Million | $-473.27K | -0.279x | -127.78% |
| 2019-03-31 | $1.80 Million | $-221.31K | -0.123x | +32.06% |
| 2018-03-31 | $373.76K | $-67.49K | -0.181x | -- |